JAHA:疾病特异性健康状况与外周动脉疾病患者长期生存之间的关系

2022-02-11 MedSci原创 MedSci原创

PAD特异性健康状况与新出现或症状恶化的PAD患者5年生存率独立相关,最近的评估是最具预测意义的。未来的工作需要更好地了解如何主动使用这些信息来优化PAD的治疗。

外周动脉疾病(PAD)仍然是一种未被充分认识和治疗的疾病,尽管它具有较高的心血管发病和死亡风险,1年事件发生率超过21%。随着疾病的进展,PAD患者可能会出现间歇性跛行和严重的肢体缺血,严重损害患者的功能和生活质量

在有症状的患者中,想获得症状缓解和患者健康状况的改善往往是PAD患者寻求血管专科治疗的主要原因。虽然外周动脉疾病(PAD)与心血管疾病发病率增加有关,死亡率仍然很高且难以预测,但准确了解PAD患者诊断时一系列的特异性健康状况可能可以预测长期死亡风险。

近日,心血管疾病领域权威杂志JAHA上发表了一篇研究文章,研究人员纳入了2011年至2015年期间在美国10个地区的PORTRAIT登记中心注册的新的或症状恶化的PAD患者。健康状况通过基线、3个月以及从基线到3个月随访的外周动脉问卷(PAQ)总结评分进行评估。研究人员使用3个月标志性和分层Cox回归模型构建了Kaplan-Meier,以评估PAQ与5年全因死亡率之间的关联。

在711名患者中(平均年龄为68.8±9.6岁,40.9%为女性,72.7%为白人;基线和3个月的平均PAQ分别为47.5±22.0和65.9±25.0),141名(19.8%)患者在长达4.1年的中位随访期间死亡。在未经调整的模型中,基线(每增加10分对应的HR为0.90;95%CI为0.84-0.97;P=0.008)、3个月(HR[95%CI]为0.87[0.82-0.93];P<0.001)和PAQ的变化(HR[95%CI]为0.92[0.85-0.99];P=0.021)均与死亡率相关。在包括评分组合在内的完全调整模型中,3个月PAQ与死亡率之间的相关性强于基线(3个月HR[95%CI]为0.85[0.78-0.92];P<0.001;C统计量为0.77)或变化值(3个月HR[95%CI]为0.79[0.72-0.87];P<0.001)。

由此可见,PAD特异性健康状况与新出现或症状恶化的PAD患者5年生存率独立相关,最近的评估是最具预测意义的。未来的工作需要更好地了解如何主动使用这些信息来优化PAD的治疗。

原始出处:

Andy T. Tran.et al.Association of Disease‐Specific Health Status With Long‐Term Survival in Peripheral Artery Disease.JAHA.2022.https://www.ahajournals.org/doi/full/10.1161/JAHA.121.022232

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1799206, encodeId=65151e99206bd, content=<a href='/topic/show?id=38e0e0670ff' target=_blank style='color:#2F92EE;'>#疾病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70670, encryptionId=38e0e0670ff, topicName=疾病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c859411, createdName=hmwwww, createdTime=Thu Jul 21 23:11:29 CST 2022, time=2022-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1899542, encodeId=170918995421a, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Sun Mar 06 14:11:29 CST 2022, time=2022-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1268755, encodeId=7ad41268e558d, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Fri Feb 11 10:11:29 CST 2022, time=2022-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511049, encodeId=9501151104996, content=<a href='/topic/show?id=5a822e867b5' target=_blank style='color:#2F92EE;'>#健康状况#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27867, encryptionId=5a822e867b5, topicName=健康状况)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Fri Feb 11 10:11:29 CST 2022, time=2022-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1593361, encodeId=d8eb159336173, content=<a href='/topic/show?id=8d1342e95fa' target=_blank style='color:#2F92EE;'>#外周动脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42795, encryptionId=8d1342e95fa, topicName=外周动脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b27818121614, createdName=wujh_7312825, createdTime=Fri Feb 11 10:11:29 CST 2022, time=2022-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1618344, encodeId=7f4b1618344cd, content=<a href='/topic/show?id=3ebc9e0210b' target=_blank style='color:#2F92EE;'>#长期生存#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97021, encryptionId=3ebc9e0210b, topicName=长期生存)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1f719885829, createdName=luckyshitiancai_42705690, createdTime=Fri Feb 11 10:11:29 CST 2022, time=2022-02-11, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1799206, encodeId=65151e99206bd, content=<a href='/topic/show?id=38e0e0670ff' target=_blank style='color:#2F92EE;'>#疾病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70670, encryptionId=38e0e0670ff, topicName=疾病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c859411, createdName=hmwwww, createdTime=Thu Jul 21 23:11:29 CST 2022, time=2022-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1899542, encodeId=170918995421a, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Sun Mar 06 14:11:29 CST 2022, time=2022-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1268755, encodeId=7ad41268e558d, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Fri Feb 11 10:11:29 CST 2022, time=2022-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511049, encodeId=9501151104996, content=<a href='/topic/show?id=5a822e867b5' target=_blank style='color:#2F92EE;'>#健康状况#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27867, encryptionId=5a822e867b5, topicName=健康状况)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Fri Feb 11 10:11:29 CST 2022, time=2022-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1593361, encodeId=d8eb159336173, content=<a href='/topic/show?id=8d1342e95fa' target=_blank style='color:#2F92EE;'>#外周动脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42795, encryptionId=8d1342e95fa, topicName=外周动脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b27818121614, createdName=wujh_7312825, createdTime=Fri Feb 11 10:11:29 CST 2022, time=2022-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1618344, encodeId=7f4b1618344cd, content=<a href='/topic/show?id=3ebc9e0210b' target=_blank style='color:#2F92EE;'>#长期生存#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97021, encryptionId=3ebc9e0210b, topicName=长期生存)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1f719885829, createdName=luckyshitiancai_42705690, createdTime=Fri Feb 11 10:11:29 CST 2022, time=2022-02-11, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1799206, encodeId=65151e99206bd, content=<a href='/topic/show?id=38e0e0670ff' target=_blank style='color:#2F92EE;'>#疾病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70670, encryptionId=38e0e0670ff, topicName=疾病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c859411, createdName=hmwwww, createdTime=Thu Jul 21 23:11:29 CST 2022, time=2022-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1899542, encodeId=170918995421a, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Sun Mar 06 14:11:29 CST 2022, time=2022-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1268755, encodeId=7ad41268e558d, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Fri Feb 11 10:11:29 CST 2022, time=2022-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511049, encodeId=9501151104996, content=<a href='/topic/show?id=5a822e867b5' target=_blank style='color:#2F92EE;'>#健康状况#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27867, encryptionId=5a822e867b5, topicName=健康状况)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Fri Feb 11 10:11:29 CST 2022, time=2022-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1593361, encodeId=d8eb159336173, content=<a href='/topic/show?id=8d1342e95fa' target=_blank style='color:#2F92EE;'>#外周动脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42795, encryptionId=8d1342e95fa, topicName=外周动脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b27818121614, createdName=wujh_7312825, createdTime=Fri Feb 11 10:11:29 CST 2022, time=2022-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1618344, encodeId=7f4b1618344cd, content=<a href='/topic/show?id=3ebc9e0210b' target=_blank style='color:#2F92EE;'>#长期生存#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97021, encryptionId=3ebc9e0210b, topicName=长期生存)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1f719885829, createdName=luckyshitiancai_42705690, createdTime=Fri Feb 11 10:11:29 CST 2022, time=2022-02-11, status=1, ipAttribution=)]
    2022-02-11 zhaohui6731
  4. [GetPortalCommentsPageByObjectIdResponse(id=1799206, encodeId=65151e99206bd, content=<a href='/topic/show?id=38e0e0670ff' target=_blank style='color:#2F92EE;'>#疾病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70670, encryptionId=38e0e0670ff, topicName=疾病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c859411, createdName=hmwwww, createdTime=Thu Jul 21 23:11:29 CST 2022, time=2022-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1899542, encodeId=170918995421a, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Sun Mar 06 14:11:29 CST 2022, time=2022-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1268755, encodeId=7ad41268e558d, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Fri Feb 11 10:11:29 CST 2022, time=2022-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511049, encodeId=9501151104996, content=<a href='/topic/show?id=5a822e867b5' target=_blank style='color:#2F92EE;'>#健康状况#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27867, encryptionId=5a822e867b5, topicName=健康状况)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Fri Feb 11 10:11:29 CST 2022, time=2022-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1593361, encodeId=d8eb159336173, content=<a href='/topic/show?id=8d1342e95fa' target=_blank style='color:#2F92EE;'>#外周动脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42795, encryptionId=8d1342e95fa, topicName=外周动脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b27818121614, createdName=wujh_7312825, createdTime=Fri Feb 11 10:11:29 CST 2022, time=2022-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1618344, encodeId=7f4b1618344cd, content=<a href='/topic/show?id=3ebc9e0210b' target=_blank style='color:#2F92EE;'>#长期生存#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97021, encryptionId=3ebc9e0210b, topicName=长期生存)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1f719885829, createdName=luckyshitiancai_42705690, createdTime=Fri Feb 11 10:11:29 CST 2022, time=2022-02-11, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1799206, encodeId=65151e99206bd, content=<a href='/topic/show?id=38e0e0670ff' target=_blank style='color:#2F92EE;'>#疾病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70670, encryptionId=38e0e0670ff, topicName=疾病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c859411, createdName=hmwwww, createdTime=Thu Jul 21 23:11:29 CST 2022, time=2022-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1899542, encodeId=170918995421a, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Sun Mar 06 14:11:29 CST 2022, time=2022-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1268755, encodeId=7ad41268e558d, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Fri Feb 11 10:11:29 CST 2022, time=2022-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511049, encodeId=9501151104996, content=<a href='/topic/show?id=5a822e867b5' target=_blank style='color:#2F92EE;'>#健康状况#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27867, encryptionId=5a822e867b5, topicName=健康状况)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Fri Feb 11 10:11:29 CST 2022, time=2022-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1593361, encodeId=d8eb159336173, content=<a href='/topic/show?id=8d1342e95fa' target=_blank style='color:#2F92EE;'>#外周动脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42795, encryptionId=8d1342e95fa, topicName=外周动脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b27818121614, createdName=wujh_7312825, createdTime=Fri Feb 11 10:11:29 CST 2022, time=2022-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1618344, encodeId=7f4b1618344cd, content=<a href='/topic/show?id=3ebc9e0210b' target=_blank style='color:#2F92EE;'>#长期生存#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97021, encryptionId=3ebc9e0210b, topicName=长期生存)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1f719885829, createdName=luckyshitiancai_42705690, createdTime=Fri Feb 11 10:11:29 CST 2022, time=2022-02-11, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1799206, encodeId=65151e99206bd, content=<a href='/topic/show?id=38e0e0670ff' target=_blank style='color:#2F92EE;'>#疾病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70670, encryptionId=38e0e0670ff, topicName=疾病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c859411, createdName=hmwwww, createdTime=Thu Jul 21 23:11:29 CST 2022, time=2022-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1899542, encodeId=170918995421a, content=<a href='/topic/show?id=6f746e94170' target=_blank style='color:#2F92EE;'>#特异性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67941, encryptionId=6f746e94170, topicName=特异性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Sun Mar 06 14:11:29 CST 2022, time=2022-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1268755, encodeId=7ad41268e558d, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Fri Feb 11 10:11:29 CST 2022, time=2022-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1511049, encodeId=9501151104996, content=<a href='/topic/show?id=5a822e867b5' target=_blank style='color:#2F92EE;'>#健康状况#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27867, encryptionId=5a822e867b5, topicName=健康状况)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Fri Feb 11 10:11:29 CST 2022, time=2022-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1593361, encodeId=d8eb159336173, content=<a href='/topic/show?id=8d1342e95fa' target=_blank style='color:#2F92EE;'>#外周动脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42795, encryptionId=8d1342e95fa, topicName=外周动脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b27818121614, createdName=wujh_7312825, createdTime=Fri Feb 11 10:11:29 CST 2022, time=2022-02-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1618344, encodeId=7f4b1618344cd, content=<a href='/topic/show?id=3ebc9e0210b' target=_blank style='color:#2F92EE;'>#长期生存#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97021, encryptionId=3ebc9e0210b, topicName=长期生存)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e1f719885829, createdName=luckyshitiancai_42705690, createdTime=Fri Feb 11 10:11:29 CST 2022, time=2022-02-11, status=1, ipAttribution=)]

相关资讯

Thorac Cancer:回顾性分析使用nivolumab治疗获得长期生存的NSCLC患者的相关因素

研究表明,与ΔNLR ≥1相比,ΔNLR <1是nivolumab治疗的晚期NSCLC患者长期生存的预测因素。

Stroke:脑出血后的长期生存、死亡原因和5年死亡率趋势

由于心血管死亡风险增加了2倍,病例的存活率显著低于对照组。吸烟、血清胆固醇和使用抗凝药物与ICH患者死亡风险增加相关。ICH患者的五年死亡率随着时间的推移保持稳定。

Circ-Heart Fail:Tafamidis对甲状腺素运载蛋白淀粉样变心肌病患者长期生存的疗效

最初在ATTR-ACT试验中接受Tafamidis治疗的患者的生存率明显高于最初接受安慰剂治疗的患者,这突出了早期诊断和治疗对于转甲状腺素蛋白淀粉样变心肌病的重要性。

Nature:哪些胰腺癌患者可获得长期生存?

来自美国纽约纪念斯隆-凯特林癌症中心的研究人员通过分析建模的方式发现,肿瘤抗原质量模型可较好地预测胰腺癌患者术后的生存期。

赵明芳教授:达可替尼有望助力患者实现高质量长期生存

2019年5月,第二代表皮生长因子受体酪氨酸激酶抑制剂(EGFR TKI)达可替尼在中国正式获批上市,成为EGFR基因敏感突变晚期非小细胞肺癌(NSCLC)患者的一线治疗选择。在将近1年的临床实践中,

Brit J Surg:肝细胞癌患者肝切除术后感染并发症对长期生存的影响

由此可见,术后感染并发症降低了肝切除术的HCC患者的长期OS和RFS。